EUVIMEDEUVIMED entdecken
Crossref

New Cancer Drug Approvals: Less Than Half Of Important Clinical Trial Uncertainties Reported By The FDA To Clinicians, 2019–22

Avi Cherla, Steven Woloshin, Anita K Wagner, Olivier J Wouters, Courtney Davis, Elias Mossialos, Huseyin Naci

Health Affairs · 2025

DOI: 10.1377/hlthaff.2024.01134 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Health Affairs, 2025. Verfasst von Avi Cherla und 6 weiteren Autor:innen. Beteiligte Einrichtung: Avi Cherla (a.j.cherla@lse.ac.uk), London School of Economics and Political Science, London, United Kingdom. Hauptthemen laut MEDLINE: United States Food and Drug Administration, Drug Approval, Antineoplastic Agents, Clinical Trials as Topic. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 45 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Uncertainties about the benefits and harms of new drugs are common at the time of drugs' approval. It is unclear to what extent the Food and Drug Administration (FDA) communicates these uncertainties in the FDA-approved prescribing information (the drug label), which is the primary channel of communication between the FDA and physicians. Although physicians might not regularly consult the drug label for prescribing decisions, other information sources used by physicians either index or incorporate information from the label. We searched FDA review documents for uncertainties identified by FDA reviewers with new cancer drugs. We considered the subset of uncertainties highlighted in the FDA's Benefit-Risk Framework as important to the FDA's approval decision. During the period 2019-22, the FDA approved fifty-two new cancer drugs. In review documents, FDA reviewers identified a total of 213 clinical trial uncertainties with new cancer drugs, 50 percent of which were considered to be important uncertainties to the FDA's approval decision. Labels for physicians reported information on 26 percent of all uncertainties and 48 percent of uncertainties that were important to the FDA's approval decision. Communicating uncertainties about the evidence of drugs in the label is essential for informing physicians about drugs' safe and effective use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

United States Food and Drug AdministrationDrug ApprovalAntineoplastic AgentsClinical Trials as TopicUnited StatesHumansUncertaintyDrug LabelingPhysicians

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Avi Cherla (a.j.cherla@lse.ac.uk), London School of Economics and Political Science, London, United Kingdom.
  • Steven Woloshin, Dartmouth College, Lebanon, New Hampshire.
  • Anita K. Wagner, Harvard University and Harvard Pilgrim Health Care Institute, Boston, Massachusetts.
  • Olivier J. Wouters, London School of Economics and Political Science.
  • Courtney Davis, King's College London, London, United Kingdom.
  • Elias Mossialos, London School of Economics and Political Science.

Zitieren

APA

Cherla, A., Woloshin, S., Wagner, A. K., Wouters, O. J., Davis, C., Mossialos, E., & Naci, H. (2025). New Cancer Drug Approvals: Less Than Half Of Important Clinical Trial Uncertainties Reported By The FDA To Clinicians, 2019–22. Health Affairs. https://doi.org/10.1377/hlthaff.2024.01134

Vancouver

Cherla A, Woloshin S, Wagner AK, Wouters OJ, Davis C, Mossialos E, et al. New Cancer Drug Approvals: Less Than Half Of Important Clinical Trial Uncertainties Reported By The FDA To Clinicians, 2019–22. Health Affairs. 2025. doi:10.1377/hlthaff.2024.01134

BibTeX
@article{Cherla2025,
  author = {Cherla, Avi and Woloshin, Steven and Wagner, Anita K and Wouters, Olivier J and Davis, Courtney and Mossialos, Elias and Naci, Huseyin},
  title = {New Cancer Drug Approvals: Less Than Half Of Important Clinical Trial Uncertainties Reported By The FDA To Clinicians, 2019–22},
  journal = {Health Affairs},
  year = {2025},
  doi = {10.1377/hlthaff.2024.01134}
}
Kostenlos starten →